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Duodenal bacterial proteolytic activity determines
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activated receptor-2
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Microbe-host interactions are generally homeostatic, but when dysfunctional, they can
incite food sensitivities and chronic diseases. Celiac disease (CeD) is a food sensitivity
characterized by a breakdown of oral tolerance to gluten proteins in genetically predisposed
individuals, although the underlying mechanisms are incompletely understood. Here we
show that duodenal biopsies from patients with active CeD have increased proteolytic
activity against gluten substrates that correlates with increased Proteobacteria abundance,
including Pseudomonas. Using Pseudomonas aeruginosa producing elastase as a model, we
show gluten-independent, PAR-2 mediated upregulation of inflammatory pathways in
C57BL/6 mice without villus blunting. In mice expressing CeD risk genes, P. aeruginosa
elastase synergizes with gluten to induce more severe inflammation that is associated with
moderate villus blunting. These results demonstrate that proteases expressed by opportu-
nistic pathogens impact host immune responses that are relevant to the development of
food sensitivities, independently of the trigger antigen.
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The human gastrointestinal tract contains proteases thatexert different and complex functions, including cell sig-naling, immune and barrier functions, and metabolism of
dietary components1,2. The release, activity, and degradation of
host proteases are tightly regulated, and imbalances in these
processes is associated with functional and chronic inflammatory
conditions, such as irritable bowel syndrome and inflammatory
bowel disease3–6. Gut bacteria and enteric opportunistic patho-
gens produce a large array of proteases that can degrade dietary
components as well as host proteins, with the potential to impact
host immune and functional pathways, leading to pro-
inflammatory responses when dysfunctional7–10. However,
our knowledge of the specific underlying microbe–dietary inter-
actions through which proteases are conducive to inflammation
is limited.
One of the most abundant sources of protein in the Western
diet is gluten, the general name given to a complex mixture of
highly immunogenic and difficult to digest glutamine and
proline-rich storage proteins in wheat and related cereals11. In
humans carrying specific risk alleles, gluten can trigger the
common food sensitivity celiac disease (CeD). Recent epidemio-
logical studies have demonstrated the growing seroprevalence, to
1.4% worldwide, of this inflammatory condition affecting the
small intestine12,13. CeD is characterized by the development of
gluten-specific T-cells, anti- tranglutaminase 2 antibodies, and an
increase of intraepithelial lymphocytes (IELs)14. Because risk
alleles (HLA-DQ2 or -DQ8) are necessary, but insufficient to
develop disease, additional environmental factors of microbial
origin have been proposed15–17. In line with this, we have recently
shown that undigested gluten can be metabolized by certain
opportunistic pathogens, such as Pseudomonas aeruginosa, lead-
ing to the production of peptides that more easily translocate
across the mucosal barrier with retained immunogenicity18.
However, it is unknown whether microbial proteolytic activity in
the small intestine directly influences host pathways important
for the maintenance of homeostasis towards dietary proteins.
Here, we demonstrate that duodenal biopsies from patients
with CeD have increased proteolytic activity against gluten pep-
tides which correlates with Proteobacteria abundance. Using
a model Proteobacterium, P. aeruginosa, which expresses the
gluten-degrading protease elastase (LasB), and its isogenic non-
functional lasB mutant19, we show an elastase-dependent
inflammatory response mediated by the protease-activated
receptor-2 (PAR-2) pathway. The importance of the interplay
between genetic and environmental factors is evidenced by the
enhancement of gluten immunopathology in a mouse model
expressing HLA-DQ8 CeD risk genes. Thus, correction of bac-
terial proteolytic imbalance in the small intestine may constitute a
new therapeutic target to prevent or ameliorate food sensitivities
triggered by specific protein antigens.
Results
Characteristic microbial proteolytic phenotype in CeD. We
collected biopsies from the second portion of the duodenum
(demographic characteristics outlined in Supplementary Table 1),
the site most commonly affected in CeD, from a cohort of
patients with and without CeD (controls) and determined the
proteolytic activity against gluten (“glutenasic” activity). Biopsies
from CeD patients produced a larger hydrolytic halo in solid
gluten-containing media compared with biopsies from controls
(Fig. 1a). In accordance with previous studies20,21, analysis of
mucosa-associated microbiota by 16S sequencing showed that
Proteobacteria and Firmicutes were the most representative
phylum in duodenal samples, followed by Bacteroidetes, Tener-
icutes, and Actinobacteria (Fig. 1b). The microbiota was specific
of each person at the genus level (Fig. 1c) and no major differ-
ences were found in alpha- or beta-diversity between groups
(Supplementary Figure 1a and 1b). However, glutenasic activity
inversely correlated with Firmicutes and Bacteroidetes and
directly correlated with Proteobacteria relative abundance
(Fig.1d). At the genus level, increased glutenasic activity corre-
lated with an increase in Proteobacteria such as Pseudomonas
and Janthinobacterium and a reduction in core members of
the duodenal microbiota, such as Lactobacillus and Clostridium
(Fig. 1e). These results suggest an association between the small
intestinal glutenasic profile in patients with CeD and the relative
abundance of certain duodenal microbial groups, notably gluten-
degrading bacteria such as Pseudomonas18,22.
LasB induces microbial shifts and innate immunity. Pathogenic
bacteria possess an arsenal of virulence factors that allow them to
survive in the host and cause disease. Among such virulence
factors, secreted extracellular proteases facilitate bacterial colo-
nization by inducing damage to host tissue and actively sub-
verting immune responses10. Due to the correlation between
glutenasic activity in duodenal biopsies and Pseudomonas, a
group previously found to metabolize gluten through LasB elas-
tase18, we chose P. aeruginosa-producing LasB elastase as a model
bacterium for in vivo analysis. P. aeruginosa strain PA1418 and a
P. aeruginosa PA14 mutant with a transposon disruption in the
lasB gene19 were used. We confirmed that the lasB mutant lacked
elastase activity compared to the wild-type (WT) P. aeruginosa
PA14 strain (Supplementary Figure 2a) in vitro. The functional
capacity of LasB to degrade gluten was confirmed using a com-
mercially available purified LasB elastase (Supplementary Fig-
ure 2b). As shown before18, degradation of gluten occurs in the
presence of supernatant extracted from P. aeruginosa PA14 WT,
but not from P. aeruginosa lasB transposon mutant (Supple-
mentary Figure 2c-left). Genetic complementation of the lasB
mutant using a vector harboring the WT lasB gene under the
control of its native promoter or an inducible arabinose promoter
restored gluten degradation of the lasB mutant, while the empty
vector did not restore activity (Supplementary Figure 2c-center).
Of note, expression of lasB into Escherichia coli resulted in
gluten degradation under the arabinose inducible promoter, but
not when repressed by the addition of glucose (Supplementary
Figure 2c-right). Altogether, these data demonstrate that LasB
is responsible for the observed in vitro gluten degradation by
P. aeruginosa.
C57BL/6 mice harboring a limited microbiota derived from the
altered Schaedler flora (clean specific pathogen free (SPF)) were
then supplemented with P. aeruginosa PA14 containing a lasB-lux
transcriptional construct integrated on its genome23 (Supple-
mentary Table 2). This reporter strain allows direct monitoring
of the lasB promoter activity via the detection of light (Fig. 2a,
Supplementary Figure 2d). The experiment confirmed the
presence of P. aeruginosa and the expression of lasB in the small
intestine. In subsequent experiments, clean SPF C57BL/6 mice
were colonized with P. aeruginosa PA14 WT, or a P. aeruginosa
PA14 mutant with a transposon disruption in the lasB gene. Mice
were then treated with gluten (gluten sensitization and challenge)
or without gluten (sham; controls) (Fig. 2b)24. Small intestinal
bacterial load was similar in P. aeruginosa PA14 WT and lasB
mutant colonized mice, with an increase of P. aeruginosa counts
in mice treated with gluten (Fig. 2c). Bacterial strains in colonized
mice maintained their in vitro proteolytic phenotype (Supple-
mentary Figure 2e) and mice colonized with P. aeruginosa PA14
WT had higher small intestinal elastolytic activity, but similar
tryptic activity levels, compared with mice colonized with lasB
mutant (Fig. 2d and Supplementary Figure 2f). This was
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Fig. 1 High proteolytic activity in celiac disease (CeD) duodenum correlates with microbiota changes. a Glutenasic activity measured in duodenal biopsies
from non-celiac disease donors (controls; n= 8) and CeD patients (n= 12). Data presented as mean ± s.e.m. where each dot represents an individual
human donor. Displayed P value was calculated by Student’s t-test. Representative bioassays are shown. b, c Relative abundance of the microbial
composition at the phylum level (b) and genus level (c) of duodenal biopsies from controls (n= 8) and CeD patients (n= 12). d, e Correlation between
microbial relative abundance at the phylum level (d) or genus level (e) and glutenasic activity in duodenal biopsies from controls (n= 8) and CeD (n= 12)
human donors. Displayed P values survived 10% false discovery rate (FDR) correction. Each dot represents individual human donor. Correlation based
on Spearman’s index
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Fig. 2 LasB induces intraepithelial lymphocytes (IELs) and microbiota shifts. a Visual expression of lasB in the small intestine (left panel) and large intestine
(right panel) of clean specific pathogen free (SPF) mice 2 weeks following colonization with a luminescent producing P. aeruginosamutant linked to the lasB
promoter (n= 3). One representative image is shown. b Protocol for gluten sensitization and challenge (gluten treatment) in clean SPF C57BL/6 mice
colonized with P. aeruginosa PA14 WT (wild-type (WT) gluten) or the lasB mutant (lasB gluten). Sham controls consisted of non-sensitized and non-gluten
challenged clean SPF C57BL/6 mice colonized with P. aeruginosa PA14 WT (WT control) or the lasB mutant (lasB control). c P. aeruginosa bacterial load in
the small intestine of clean SPF C57BL/6 colonized with P. aeruginosa PA14 WT or lasB mutant with gluten treatment (gray bars; n= 4 WT, n= 5 lasB)
or without gluten treatment (white bars; n= 5 WT, n= 4 lasB). d Elastase activity measured in the small intestine of clean SPF C57BL/6 mice colonized
with P. aeruginosa PA14 WT or the lasB mutant with gluten treatment (gray bars; n= 4 WT, n= 5 lasB) or without gluten treatment (white bars; n= 5 WT,
n= 4 lasB). e β-Diversity Bray–Curtis dissimilarity principal coordinates analysis (PCoA) plot of microbiota profiles from clean SPF C57BL/6 mice colonized
with P. aeruginosa PA14 WT (n= 10) or the lasBmutant (n= 9). Each dot represents an individual mouse. Differences between bacterial communities were
tested by permutational multivariate analysis of variance (PERMANOVA) using Qiime. f Quantitative measurement of IELs/100 enterocytes in small
intestinal villi tips of clean SPF C57BL/6 mice colonized with P. aeruginosa PA14 WT or the lasB mutant, with gluten treatment (gray bars; n= 4 WT, n= 5
lasB) or without gluten treatment (white bars; n= 5 WT, n= 4 lasB). g Small intestinal villus-to-crypt ratios of clean SPF C57BL/6 mice colonized
with P. aeruginosa PA14 WT or the lasB mutant, with gluten treatment (gray bars; n= 4 WT, n= 5 lasB) or without gluten treatment (white bars; n= 5 WT,
n= 4 lasB). Data for c, d, f, g are presented as mean ± s.e.m. where each dot represents an individual mouse. Displayed P values were calculated by a one-
way analysis of variance (ANOVA) with Tukey's post-hoc test
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associated with differences in small intestinal microbiota
composition between the two groups (Fig. 2e and Supplementary
Figure 2g). While P. aeruginosa PA14 WT, but not lasB mutant
colonized mice, had increased small intestinal IEL (CD3-positive
cells (CD3+)) counts (Fig. 2f), there were no differences in
villus-to-crypt ratios (Fig. 2g), levels of anti-gliadin antibodies
(Supplementary Figure 2h), or in the small intestinal expression
of 254 inflammatory genes (Nanostring Mouse Inflammation
Panel; raw data included in Expression Omnibus database (GEO,
GSE125983) under the Umbrella project PRJNA518891). These
data show that in C57BL/6 mice, LasB is associated with higher
IEL counts and altered small intestinal microbiota profiles, in
the absence of significant mucosal damage.
LasB is pro-inflammatory in the absence of a microbiota. To
rule out possible contributions of shifts in clean SPF microbiota
profiles induced by the presence of the opportunistic pathogen,
germ-free C57BL/6 mice were monocolonized with P. aeruginosa
PA14 WT, or its lasB mutant (Fig. 3a). Using the lasB-lux tran-
scriptional reporter strain, we confirmed that the lasB promoter
was transcriptionally active under these colonization conditions
(Supplementary Figure 3a). On killing of mice, we recovered
103–104 colony-forming units (cfu)/g of small intestinal content
in each group (Fig. 3b). P. aeruginosa PA14 WT-monocolonized
mice had higher glutenasic and elastolytic activity (Fig. 3c, d), but
not tryptic activity (Supplementary Figure 3b) in small intestinal
washes, as well as higher small intestinal IEL counts (Fig. 3e)
compared with mice colonized with the lasB mutant. Flow
cytometry confirmed that colonization with P. aeruginosa PA14
WT increased total numbers of IELs positive for CD45, CD3, and
CD103 (Supplementary Figure 3c and 3d).
Small intestinal washes from mice monocolonized with
P. aeruginosa PA14 WT also had higher mucolytic activity
compared with washes from mice colonized with the lasB mutant
(Supplementary Figure 3e). We thus investigated mucus invasion
by P. aeruginosa using 16S-fluorescence in situ hybridization
(FISH). P. aeruginosa PA14 WT encroached upon the epithelial
layer with greater capacity than the lasB mutant, suggesting a
higher invasive phenotype facilitated by LasB elastase (Supple-
mentary Figure 3f). We did not find evidence of Pseudomonas
translocation to the spleen (Supplementary Figure 3g), suggesting
that these effects were limited to the mucosal surface.
No differences in messenger RNA expression of a panel of
genes involved in immune pathways were found between groups,
using whole small intestinal tissues (Nanostring Mouse Inflam-
mation Panel; raw data included in GEO (GSE125983) under the
Umbrella project PRJNA518891). Analysis using an isolated cell
compartment enriched for IELs revealed that the transcription of
40 genes was significantly increased in mice monocolonized with
P. aeruginosa PA14 WT compared to mice monocolonized with
the lasB mutant. The functions of these genes related to IEL
activation and cytotoxicity, barrier function, and resistance to
infection (Fig. 3f and Supplementary Figure 4a). Using Ingenuity
Pathway Analysis (IPA) software (Qiagene), overexpressed genes
were found to be related to canonical pathways relevant to
infection or recognition of bacteria (ifng, il6, il17a, tnf, and il22),
and inflammation mediated by several pathways including G
protein-coupled receptor signaling (c3ar1, cysltr1, stat3). Path-
ways were associated to CD3+ cells and cell death based on
overexpression of genes such as fasl, tgfb1, ltb, lta, and map3k9.
The changes in gene expression were also linked with adaptive








































































































































































Fig. 3 LasB induces a pro-inflammatory response in the absence of microbiota. a Protocol for monocolonization of C57BL/6 mice with P. aeruginosa PA14
wild-type (WT) or the lasB mutant. b P. aeruginosa bacterial load recovered in the small intestine of WT (n= 6) and lasB mutant (n= 5) colonized mice
3 weeks post colonization. c Luminal small intestinal glutenasic activity from mice monocolonized with P. aeruginosa PA14 WT (n= 6) or the lasB mutant
(n= 5). Representative bioassays are shown. d Luminal small intestinal elastase activity from mice monocolonized with P. aeruginosa PA14 WT (n= 6) or
the lasBmutant (n= 5). e Quantitative measurement of intraepithelial lymphocytes (IELs)/100 enterocytes in small intestinal villi tips of P. aeruginosa PA14
WT (n= 6) or lasB mutant (n= 5) monocolonized mice. f Heat map of gene expression in the small intestinal IEL compartment of mice colonized with P.
aeruginosa PA14 WT (n= 3) or the lasB mutant (n= 3) assessed by NanoString nCounter gene expression. Only statistically different genes generated by
nSolver 2.5 using Student’s t-test and based on bacterial colonization are shown. Data for b–e are presented as mean ± s.e.m. where each dot represents an
individual mouse. Displayed P values were calculated by Student’s t-test
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complex (MHC) class II genes and immunoglobulin production
(Supplementary Figure 4b). Thus, our experimental data suggest
that LasB-producing P. aeruginosa is sufficient to promote a
widespread pro-inflammatory molecular signature in the IEL
compartment of the duodenum.
Cleavage of PAR-2 by LasB mediates IEL increase. Protease-
activated receptors (PARs) are a subfamily of G protein-coupled
receptors that are activated by the proteolytic cleavage of part
of their extracellular domain25,26. Using a transgenic cell
line harboring PAR-2 tagged to luciferase27, we found that
P. aeruginosa PA14 WT, but not the lasB mutant, cleaved the
external domain of PAR-2, suggesting that bacterial elastase
is responsible for the activation of this pathway (Fig. 4a). We
confirmed that genetic complementation of the P. aeruginosa lasB
transposon mutant with the lasB-expressing plasmid restored
the capacity of the strain to degrade the external domain of
PAR-2 (Supplementary Figure 5a). In addition, transformation of
an E. coli strain (with no capacity to degrade PAR-2) with
the plasmid coding for lasB resulted in high degradation of
the PAR-2 receptor under the arabinose inducible promoter and
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Fig. 4 LasB induces a pro-inflammatory response through protease-activated receptor- 2 (PAR-2). a In vitro cleavage of the external domain of PAR-2 by
P. aeruginosa PA14 wild-type (WT) (n= 3 biological replicates) and the lasB mutant (n= 3 biological replicates). Data presented as mean ± s.e.m where
each dot represents one biological replicate. b Protocol for monocolonization of germ-free C57BL/6 mice and protease-resistant PAR-2 mutant mice
(PAR38E-PAR2) with P. aeruginosa PA14 WT. c P. aeruginosa bacterial load recovered in the small intestine of monocolonized C57BL/6 mice (n= 4) and
PAR38E-PAR2 mice (n= 4). d Luminal small intestinal glutenasic activity from C57BL/6 mice (n= 4) and PAR38E-PAR2 mice (n= 4) monocolonized with
P. aeruginosa PA14 WT. Representative bioassays are shown. e Luminal small intestinal elastase activity from C57BL/6 mice (n= 4) and PAR38E-PAR2
mice (n= 4) monocolonized with P. aeruginosa PA14 WT. f Quantitative measure of intraepithelial lymphocytes (IELs)/100 enterocytes in small intestinal
villi tips of C57BL/6 mice (n= 4) and R38E-PAR2 mice (n= 4) monocolonized with P. aeruginosa PA14 WT. g Heat map of gene expression in the IEL
compartment of the small intestine of C57BL/6 mice (n= 4) and PAR38E-PAR2 mice (n= 4) monocolonized with P. aeruginosa PA14 WT assessed by
NanoString nCounter gene expression. Only statistically different genes generated by nSolver 2.5 using Student’s t-test and based on bacterial colonization
are shown. Data for c–e are presented as mean ± s.e.m. where each dot represents an individual mouse. Displayed P values were calculated by Student’s
t-test
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glucose (Supplementary Figure 5a). These results demonstrate the
capacity of LasB to cleave the external domain of PAR-2.
To test the role of PAR-2 in the immune response mediated
by LasB in vivo, mice monocolonized with P. aeruginosa PA14
WT were intraperitoneally injected every 3 days with a PAR-2
antagonist or vehicle for 2 weeks (Supplementary Figure 5b).
Both groups showed similar bacterial load and glutenasic
activities in the small intestine (Supplementary Figure 5c and
5d). However, mice monocolonized with P. aeruginosa PA14
WT and treated with the GB83 PAR-2 antagonist had lower IEL
counts compared to mice treated with vehicle (Supplementary
Figure 5e), suggesting a role for PAR-2.
Protease-resistant PAR-2 mutant (R38E-PAR2) mice were next
used to determine the role of the external domain of PAR-2
in LasB-mediated innate immune responses (Supplementary
Figure 5f). Supplementation of P. aeruginosa PA14 WT to SPF
C57BL/6 mice, but not to SPF R38E-PAR2 mice, led to higher
small intestinal IEL counts, despite both groups harboring similar
luminal small intestinal elastase activity (Supplementary Figure 5g
and 5h). To rule out other microbial contributions, germ-free
R38E-PAR2 and C57BL/6 mice were then monocolonized with
P. aeruginosa PA14 WT (Fig. 4b). We recovered similar counts
of P. aeruginosa in the small intestine, and there was no difference
in glutenasic or elastase activity between groups (Fig. 4c–e).
However, monocolonization increased small intestinal IEL
counts only in C57BL/6 mice, suggesting PAR-2 cleavage of the
external domain mediates the innate activation mediated by LasB
(Fig. 4f). Gene expression analysis in the isolated cell compart-
ment enriched for IELs revealed that monocolonization led
to overexpression of a total of 20 inflammatory genes, and
underexpression of 8 genes in C57BL/6 mice compared with
R38E-PAR2 mice (Fig. 4g). Specifically, genes related to recogni-
tion of bacteria (tlr2, tlr8, and nod1) and apoptosis (tgfb1, lta, and
fasl) were increased in C57BL/6 mice, while genes such as Il18rap
and Mapk3 were increased in R38E-PAR2 mice. Expression of
genes specifically increased by P. aeruginosa WT in C57BL/6 mice
(Fig. 3f) related to CD3+ cells and cell death (tgfb1, lta, ltb, and
fasl) were underexpressed in R38E-PAR2 mice monocolonized
with P. aeruginosa WT (Fig. 4g and Supplementary Figure 5i).
These results suggest that proteolytic cleavage of PAR-2 receptor
is key for the IEL responses induced by bacterial elastase.
LasB enhances gluten-induced pathology. We used an animal
model of gluten sensitivity to investigate the effects of bacterial
proteases and innate immune activation in a genetically suscep-
tible host. We have previously shown that responses to gluten in
mice expressing the HLA-DQ8 susceptibility gene are microbiota
dependent, with unclear mechanisms. Clean SPF NOD/DQ8 mice
are protected from developing immunopathology, whereas mice
that harbor a more diverse and complex intestinal microbiota
that includes Proteobacteria develop moderate immunopathology
when sensitized with gluten28. Therefore, we colonized clean SPF
NOD/DQ8 mice with P. aeruginosa PA14 WT or the lasB mutant,
and treated them with or without gluten (Fig. 5a). P. aeruginosa
successfully colonized the small intestine, where higher elastase
activity was observed in P. aeruginosa PA14 WT compared with
lasB mutant colonized mice (Fig. 5b, c). No differences in tryptic
activity were observed between groups (Supplementary Figure 6a).
Differences in clean SPF microbiota profiles (Supplementary
Figure 6b and 6c) between the two groups of mice were also
detected. Compared to mice colonized with the lasB mutant,
P. aeruginosa PA14 WT-colonized mice had higher small intest-
inal IEL counts (Fig. 5d), increased PAR-2 expression in the small
intestine epithelium (Supplementary Figure 6d), and increased
inflammatory gene expression in whole small intestinal sections,
which were independent of gluten treatment. Genes related to
resistance to infection, cytotoxicity, cell death, and G protein-
coupled receptor signaling such as c3ar1, hif1α, il22, and ifnγ were
highly expressed in mice colonized with P. aeruginosa PA14 WT
(Fig. 5e and Supplementary Figure 6e). Gluten treatment was
associated with higher expression of additional inflammatory
genes such as il18 (Fig. 5f and Supplementary Figure 6f). More-
over, the presence of P. aeruginosa PA14 WT resulted in lower
small intestinal villus-to-crypt ratios (Fig. 5g), and higher anti-
gliadin antibody titers in small intestinal washes, only after gluten
treatment (Supplementary Figure 6g). Thus, in a mouse model
with genetic susceptibility, LasB enhances gluten immunopathol-
ogy through gluten-independent mechanisms.
CeD microbiota increases proteolytic activity and IELs. The
previous experiments determined a critical role of bacterial glu-
tenasic activity in host immune responses to dietary protein
antigen; however, its role in the presence of a bacterial commu-
nity derived from the human gut is unclear. To address this, we
colonized germ-free C57BL/6 mice using duodenal aspirates from
9 randomly selected donors with active CeD (n= 4) or without
CeD (controls; n= 5) for 3 weeks (Fig. 6a). Duodenal aspirates
come from the same cohort as Fig. 1. Compared with fecal
slurries, duodenal aspirates have a low bacterial yield, thus each
donor allowed for the colonization of 2–3 mice after adjusting for
equal bacterial concentration in the inoculum. Small intestinal
microbiota profiles in recipient mice clustered significantly by
donor (Fig. 6b). All the bacteria found in the small intestine of the
recipient mice (>1% abundance) were present in the donors and
between 20 and 80% of the total human microbiota composition
was transferred into the mice (Supplementary Figure 7a and 7b).
No differences in small intestinal microbiota composition (Sup-
plementary Figure 7a) or diversity (Fig. 6b) were found in reci-
pient mice based on CeD diagnosis. Although individual donor-
related differences were observed, pooled group data revealed that
mice colonized with microbiota from CeD had higher small
intestinal glutenasic activity (Fig. 6c) and higher small intestinal
IEL counts (Fig. 6d). Moreover, there was a significant correlation
between glutenasic activity and IEL counts (Fig. 6e). As in human
duodenal biopsies, glutenasic activity inversely correlated with
Firmicutes and directly correlated with Proteobacteria relative
abundance in the small intestine of recipient mice (Fig. 6f). Taken
together, these results indicate that the increased small intestinal
microbial glutenasic activity in CeD patients can be transferred
to germ-free mice where it associates with higher IEL counts.
Discussion
Approaches to prevent or treat food sensitivities require knowl-
edge of the complex mechanisms and signaling events by which
environmental factors interact with food triggers to produce a
response in the host29–31. Here, we demonstrate that duodenal
biopsies from patients with active CeD, a condition that develops
when oral tolerance to dietary gluten is broken, have increased
proteolytic activity against gluten peptides compared with healthy
controls that correlates with Proteobacteria abundance. Several
clinical and cohort studies have linked intestinal infections
and changes in the intestinal microbiota, including an increase
in Proteobacteria, with CeD onset or activity15. These microbial
changes in CeD could represent a disease-triggering or -mod-
ifying factor, or they could be a consequence of disease driven by
intestinal damage or malabsorption. However, knowledge of
specific mechanisms by which the small intestinal microbiota
influence CeD pathogenesis is lacking.
The ubiquitous presence of gluten in the diet, and the resis-
tance of gluten proteins to gastrointestinal digestion11, allow
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for the presence of long immunogenic peptides in the gut lumen
that are substrates for microbial metabolism32,33. Proliferation
of specific bacterial groups with the ability to metabolize
gluten could promote sensitivity in a predisposed host. Oppor-
tunistic pathogens, including members of Proteobacteria such
as P. aeruginosa isolated from the duodenum of CeD patients,
can metabolize gluten predigested by human proteases into
shorter immunogenic peptides that permeate better through
the barrier and stimulate human gluten-specific T cells18. How-
ever, it is unknown whether the proteases produced by these
opportunistic pathogens can independently disrupt host inflam-
matory pathways relevant for the generation of sensitivity to
dietary protein antigens. Here, we found a correlation between
Pseudomonas relative abundance and increased proteolytic
activity against gluten in the small intestine of patients with CeD,
which can be transferred to gnotobiotic mouse models.
We first performed a series of gnotobiotic experiments using
clean SPF C57BL/6 mice co-colonized with P. aeruginosa PA14
WT or a mutant lacking lasB activity. We detected different small
intestinal microbiota profiles between the two groups, suggesting
the presence of bacterial protease could shift the resident
microbiota. This is consistent with clinical studies describing a
high abundance of opportunistic pathogens in the microbiota of
patients with active CeD34. However, monocolonization of germ-
free mice with P. aeruginosa PA14 WT, or the lasB mutant,
indicated a protease–host interaction was sufficient to induce the
inflammatory phenotype. P. aeruginosa-producing elastase led to
higher IELs and overexpression of several pro-inflammatory
genes in the IELs isolated from the small intestinal mucosa,
including tgfb and tnf, two cytokines involved in IEL activity35,36.
The expression of ifng, a cytokine central to the pathogenesis of
CeD37, and fasl, a mediator of IEL cytotoxicity38, were upregu-
lated in the compartment enriched for IELs. A number of genes
involved in resistance to infection such as il17, il22, and il6 were
also increased39,40. The overexpression of these genes suggests a
response related to infection, as well as activation of an innate
immune response (c3ar, cysltr1, stat3), that could lead to cell





























































































































































Fig. 5 LasB enhances gluten sensitivity in genetically predisposed mice. a Protocol for gluten sensitization and challenge (gluten treatment) of clean specific
pathogen free (SPF) NOD/DQ8 mice colonized with P. aeruginosa PA14 WT (wild-type (WT) gluten) or the lasB mutant (lasB gluten). Sham controls
consisted of non-sensitized and non-gluten challenged clean SPF NOD/DQ8 mice colonized with P. aeruginosa PA14 WT (WT control). b P. aeruginosa
bacterial load in the small intestine of clean SPF NOD/DQ8 colonized with P. aeruginosa PA14 WT or the lasBmutant, treated with gluten (gray bars; n= 10
WT, n= 4 lasB) or without gluten (white bars; n= 6). c Luminal small intestinal elastase activity of clean SPF NOD/DQ8 mice colonized with P. aeruginosa
PA14 WT or the lasB mutant, treated with gluten (gray bars; n= 10WT, n= 4 lasB) or without gluten (white bars; n= 6). d Quantitative measure of
intraepithelial lymphocytes (IELs)/100 enterocytes in small intestinal villi tips in clean SPF NOD/DQ8 mice colonized with P. aeruginosa PA14 WT or
the lasB mutant, treated with gluten (gray bars; n= 10 WT, n= 4 lasB) or without gluten (white bars; n= 7). e, f Heat map of significantly altered genes
in whole small intestinal tissue of clean SPF NOD/DQ8 mice (n= 4/group), when comparisons were performed between P. aeruginosa PA14 WT and
lasB mutant colonized mice (e) or when comparisons were performed between gluten treated and control mice (f). Gene expression was assessed by
NanoString nCounter gene expression and only significantly altered genes generated by nSolver 2.5 using multiple t-tests are shown. g Small intestinal
villus-to-crypt ratios in clean SPF NOD/DQ8 mice colonized with P. aeruginosa PA14 WT or the lasBmutant, treated with gluten (gray bars; n= 10 WT, n=
4 lasB) or without gluten (white bars; n= 8). Data for b–d, g are presented as mean ± s.e.m. where each dot represents an individual mouse. Displayed
P values were calculated by one-way analysis of variance (ANOVA) with Tukey's post-hoc test
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Fig. 6 Celiac duodenal microbiota induces proteolytic activity and intraepithelial lymphocytes (IELs). a Protocol for the colonization of germ-free C57BL/6
mice with human small intestinal aspirates from celiac disease (CeD) patients (n= 4) or controls (n= 5). b Beta-diversity of small intestinal microbiota
profiles of recipient mice colonized with human aspirates of patients with CeD and without CeD (controls), using Bray–Curtis dissimilarity represented as
non-metric multidimensional scaling (NMSD). Differences between bacterial communities were tested by permutational multivariate analysis of variance
(PERMANOVA) using Qiime. Each donor was used to colonize 2–3 mice, and each dot represents an individual mouse. c Glutenasic activity per donor (left
side) and pooled (right side), measured in the small intestine of mice colonized with small intestinal aspirates from control or CeD donors. Representative
bioassays are shown. d Quantitative measurement of IELs/100 enterocytes in small intestinal villi tips of mice colonized with small intestinal aspirates from
control or CeD donors. IEL counts per donor (left panel) and pooled counts (right panel) are shown. Data for c, d are presented as median with interquartile
range and whiskers extending from minimum to maximum. Each dot represents an individual mouse. Each donor, as indicated by a different color, was used
to colonize 2–3 mice. Displayed P values were calculated by Mann–Whitney test. Tissue from one recipient mouse receiving CeD donor 2 presented
technical difficulties during embedding and processing and was dropped out. e Correlation between glutenasic activity and IEL counts in the small intestine
of mice colonized with small intestinal aspirates (n= 23). Each dot represents an individual mouse. Correlation based on Spearman's index. f Correlation
between relative abundance of Proteobacteria and Firmicutes and small intestinal glutenasic activity of mice colonized with small intestinal aspirates (n=
23). Each dot represents an individual mouse. Displayed P values from Proteobacteria and Firmicutes survived 10% false discovery rate (FDR) correction.
Correlation based on Spearman's index
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is also linked to CD3+ IEL increase and adaptive immune
responses mediated by MHC class II genes and immunoglobulin
production, which are characteristic of CeD36. However, despite
the induction of a pro-inflammatory molecular signature within
the IEL compartment of C57BL/6 mice colonized with P. aeru-
ginosa PA14 WT, histological assessment did not reveal villus
atrophy.
Mice monocolonized with P. aeruginosa PA14 WT had a
higher presence of bacteria within the mucus layer, suggesting
that bacterial elastase is also used for mucus invasion. This
encroachment toward the mucosal surface was not associated
with bacterial translocation to secondary lymphoid organs, and
thus supports a physical mechanism through which P. aeruginosa
elastase could facilitate contact with host epithelial cells to pro-
mote a localized pro-inflammatory response. As a molecular
mechanism, we investigated the role of PARs, G protein-coupled
receptors that are activated by limited proteolysis of their extra-
cellular N-terminal domain, and are ubiquitously expressed in the
gut. Activation of PARs induces a wide array of pro-inflammatory
and proliferative effects1,25,26. Our study reveals that P. aerugi-
nosa LasB cleaves the external domain of PAR-2 in vitro, sug-
gesting activation of the receptor. This cleavage was also noted
with an elastase-producing celiac clinical isolate (P. aeruginosa
X46.122), which also induced an increase of IELs in clean SPF
C57BL/6 mice (Supplementary figure 8). Thus, the phenotype
described is not restricted to P. aeruginosa PA14. P. aeruginosa
has previously been shown to activate or disable PAR-241,42.
Specifically, Dulon et al.41 demonstrated that LasB cleaves the
PAR-2 receptor thereby altering the host innate defense
mechanisms. Here, administration of P. aeruginosa PA14 WT to
protease-resistant PAR-2 mutant mice did not increase IEL
counts, implicating PAR-2 signaling, and specifically external
domain cleavage by LasB (canonical or alternative activation), in
the IEL response. It is also possible that other PARs such as
PAR-1, -2, -3, and -4 could participate in the P. aeruginosa LasB-
triggered events. There are several examples for biologically
relevant PAR-1-PAR-243,44 and PAR-3-PAR-2 cross-activation45.
However, it is important to mention that the protease-resistant
PAR-2 mutant mice still respond to cross-activation by other
PARs46, strongly supporting that PAR-2 cleavage, rather than
other receptor crosstalk, directly mediates the observed effects.
Gene expression analysis revealed a reduction in pro-
inflammatory genes mediating bacteria recognition (tlr2, tlr8,
and nod1) in R38E-PAR2 mice colonized with P. aeruginosa
PA14 WT, consistent with several studies linking PARs with the
normal signaling of pathogen-associated molecular patterns46–48.
In addition, genes related to apoptosis and cell death, including
those specifically overexpressed in C57BL/6 mice monocolonized
with P. aeruginosa PA14 WT (tgfb1, lta, ltb and fasl), were
reduced in R38E-PAR2 mice. Some of these genes mediate CD3+
IEL increase (tgfb1) and their pathogenic capacity (fasl), which
are characteristic in active CeD38,49–51. Thus, we demonstrate
a role of microbial elastase in the recruitment of IELs in the
small intestine. Although this mechanism has no major patho-
logical consequences in C57BL/6 mice, it could contribute to
villus damage in a genetically predisposed host.
Mice expressing the HLA-DQ8 gene in NOD background
(NOD/DQ8) do not develop gluten immunopathology if they
are reared in clean SPF conditions that lack pathobionts28.
Here we found that colonization of clean SPF NOD/DQ8 mice
with P. aeruginosa PA14 WT led to an innate immune activation
and reduced villus-to-crypt ratios after gluten exposure. Thus,
genetically susceptible mice protected by the presence of a
innocuous microbiota develop moderate villus blunting when
supplemented with elastase-producing P. aeruginosa and gluten,
but not when supplemented with the same strain lacking elastase
activity. Gene expression analysis indicated that P. aeruginosa
PA14 WT induced a pro-inflammatory cascade in whole small
intestinal tissues of NOD/DQ8 mice involving ifng and il22.
Genes related to cell death such as hif1a or fasl, which have
previously been linked to CeD38,52, were also highly expressed
in NOD/DQ8 mice colonized with P. aeruginosa PA14 WT. The
results suggest that elastase activity in P. aeruginosa PA14 WT
drives pathways conducive to apoptosis in NOD/DQ8 mice,
and illustrate the complexity of interactions between the dietary
triggers, genetic predisposition, and specific microbial-induced
pathways.
Microbiota-modulating therapies are currently employed
empirically in clinical practice with little pathophysiological
understanding. Given the increasing prevalence of adverse reac-
tions to gluten and the recognition of the gluten-free diet as
an imperfect therapy, there is interest in the development of
adjuvant therapies to dietary restriction53. Our results identify
an opportunistic pathogen-driven mechanism, through protease
production and PAR-2 signaling, that could be exploited ther-
apeutically to treat gluten-related disorders and other food
sensitivities. Although animal models do not perfectly mimic
human disease, models with a permissive genetic risk colonized
with bacteria isolated from the human gut can be exploited to
decipher pathways of interest that will inform clinical research28.
The current results are consistent with previous studies showing
dysregulation of eukaryotic protease inhibitors, such as elafin,
in the duodenum of CeD patients54, and the improvement of
gluten sensitivity in mouse models after using bacteria producing
specific protease inhibitors55. Future studies should investigate
the modulation of this specific pathway in patients with CeD
non-responsive to the gluten-free diet or in the prevention of
other food sensitivities triggered by protein antigens.
Methods
Human samples. We recruited a cohort of adult celiac patients (n= 12) attending
the McMaster University Celiac Clinic (http://farncombe.mcmaster.ca/celiac-
disease-clinic/) who were scheduled for upper gastrointestinal endoscopy. CeD
patients showed clinical symptoms of disease, positive celiac serology markers
(anti-tissue transglutaminase antibodies, DQ2/DQ8 genes), and a degree of
duodenal mucosal atrophy, classified as type 3 according to the Marsh classifica-
tion. Non-CeD controls (n= 8) were patients who attended the McMaster
University Digestive Diseases Clinic for investigation of anemia, abdominal pain,
or gastroesophageal reflux disease, and had normal endoscopy, with negative celiac
serology, negative Helicobacter pylori test, and a normal villus structure by biopsy
examination. Other organic diseases such as inflammatory bowel disease were also
ruled out. CeD patients and controls were sex and age matched (Supplementary
Table 1). None of the adults included in the study had been treated with antibiotics
or proton-pump inhibitors for at least 1 month prior to the sampling time. All
subjects signed the written informed consent and the study was approved by the
Hamilton Integrated Research Ethics Board (REB # 12–599). Ethical regulations
for work with humans and human samples were meticulously followed in the
study. Biopsies from the second portion of the duodenum and aspirates from the
small intestine were collected in all participants. The samples were frozen and
stored until analysis.
Mice. Female and male 8- to 12-week-old germ-free C57BL/6 mice were generated
by two-stage embryo transfer and bred under germ-free conditions in the Axenic
Gnotobiotic Unit (AGU) at McMaster University. SPF C57BL/6 mice were ori-
ginally purchased from Taconic and subsequently bred at McMaster’s Central
Animal Facility (CAF). Germ-free female and male 8 to 12-week-old Non-Obese
Diabetic HLA-DQ8 (NOD/DQ8) transgenic mice24,56 were generated by two-stage
embryo transfer and bred in the AGU at McMaster University. Protease-resistant
PAR-2 mutant breeding pairs (R38E-PAR2)46 were originally provided by Wol-
fram Ruf from Johannes Gutenberg University Mainz and bred at McMaster’s CAF
under SPF conditions. R38E-PAR2 mice were re-derived germ-free by two-stage
embryo transfer and bred under germ-free conditions in the AGU at McMaster
University. Clean SPF mice originated from germ-free mice that were naturally
colonized by co-housing with female mouse colonizers harboring altered Schaedler
flora and bred for three generations in individually ventilated cage racks28. All
mouse colonies were fed an autoclaved gluten-free mouse diet (Harlan, Indiana-
polis, IN) for two generations (Harlan Laboratories, Indianapolis, IN) until used in
experiments. All mice had unlimited access to food and water. All experiments
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were conducted with approval from the McMaster University Animal Care
Committee and McMaster Animal Research Ethics Board (AREB) in an amend-
ment to the Animal Utilization Protocol (AUP#170836). Ethical regulations for
animal testing and research were followed in the study. Mice were sex and age
matched.
Bacterial strains and growth conditions. We used the laboratory wild-type P.
aeruginosa PA14 (burn patient isolate) for mouse experiments19. P. aeruginosa lasB
mutant strain (lasB::MAR2xT7) from the available non-redundant transposon
mutant library in strain PA14 was also used19. These strains were grown in Tryptic
soy broth with gentamicin (50 µg/ml) to select for the Tn5 transposon. P. aeru-
ginosa X46.1 isolated from the duodenum of a celiac patient was used in some
experiments22. Proteolytic activities and phenotypes of all strains were monitored
using gluten media. To measure expression from the lasB promoter in vivo, a
plasB-luxCDABE transcriptional reporter23 was integrated at the CTX integration
site in the P. aeruginosa PA14 strain. Tetracycline at a concentration of 150 µg/ml
was used to maintain the plasmids in P. aeruginosa strains, while 5 µg/ml was used
for E. coli strains. Chemically competent NEB 5-alpha competent E. coli strain,
derivate of the E. coli DH5α strain, and E. coli HB101 strain were used for plasmid
construct transformation (New England Biolabs, Massachusets, USA). E. coli
strains were grown in Luria Bertani (LB) broth at 37 °C. All bacterial strains and
vectors used in the study are described in Supplementary Table 2.
Cloning and complementation of lasB transposon mutant. A 1.8 bp DNA
fragment containing the lasB gene, the endogenous terminator, and 300 bp of the
upstream region were PCR amplified from P. aeruginosa PA14 using Q5 high
fidelity polymerase (NEB, Massachusetts, USA) with the primers lasBF-end 5′-
GTCGACTCTAGAGGATCCCCTGGCCCCTCGCTGAGCGC-3′ and lasBR-end
5′- AGAATTCGAGCTCGGTACCCCTGGCGGAAGACGGCTTGAGC-3′. A
second fragment containing the lasB gene was also PCR amplified from P. aeru-
ginosa PA14 using lasBF-ara 5′-AGAATTCGAGCTCGGTACCCCAGGAGAAC
TGAACAAGATGAAGAAGG-3′ and lasBR-ara 5′-GTCGACTCTAGAGGATCC
CCTTACAACGCGCTCGGGCA-3′. Then, both fragments were cloned into the
commercial plasmid pHERD26T using Gibson cloning (New England). Briefly, the
pHERD26T vector57 backbone was PCR amplified using the primers
pHERD26TgF 5′-GGGGATCCTCTAGAGTCGAC-3′ and pHERD26TgR 5′-GGG
TACCGAGCTCGAATTCTTATCAGATC-3′ with Phusion Hot Start II DNA
polymerase (ThermoFisher Scientific, Massachusetts, USA). The primers used in
this section are shown in Supplementary Table 3. The gene PCR products con-
taining lasB were then cloned into the pHERD26T PCR-amplified plasmid back-
bone and transformed in NEB 5-alpha competent E. coli strain (New England
Biolabs). Plasmid constructs are shown in Supplementary Table 2. E. coli strains
carrying pHERD26T and pHERD26T containing the lasB gene (pHERD26T-lasB)
were then conjugated into P. aeruginosa lasB transposon mutant by triparental
mating, using pRK2013 as the mobilizing plasmid58. Tetracycline was used at a
concentration of 150 µg/ml for plasmid selection while gentamicin was used at 50
µg/ml for E. coli counter selection. For the expression of lasB in E. coli under the
arabinose promoter, cells were grown in the presence of 0.2% of glucose (as
control) or 0.2% of arabinose.
Cell line. Chinese hamster ovary (CHO) cells, in which NanoLuc luciferase (Nluc)
is placed at the PAR-2 N terminus, were used to measure PAR-2 cleavage
(Supplementary Table 2)27. Briefly, Nluc reporter tag was cloned in frame with the
human form of PAR-2 complementary DNA and its stop codon was mutated to
insert eYFP tag (Nluc-hPAR2-eYFP). A stable CHO cell line was developed using
positive selection to plasmocin antibiotic. The cell line was routinely grown in
Dulbecco’s minimal essential medium supplemented with 1 mM sodium pyruvate,
10% fetal bovine serum, and 2.5 µg/ml plasmocin (Invitrogen/ThermoFisher,
Carlsbad, CA) on Nunclon Delta Surface Cell Culture Flasks (Sigma-Aldrich,
St. Louis, MO) at 37 °C in a 5% CO2 in a humidified incubator.
Mouse colonizations and bacterial supplementations. For monocolonizations,
germ-free mice received one oral gavage with P. aeruginosa PA14 WT or an
isogenic variant lacking elastase (lasB mutant;108 cfu/mouse). Clean SPF mice
(altered Schaedler flora-colonized)59 co-colonized with P. aeruginosa received one
oral gavage with P. aeruginosa PA14 WT, the lasB mutant, or P. aeruginosa X46.1
(1010 cfu/mouse). For SPF experiments, protease-resistant PAR-2 mutant and
C57BL/6 mice were supplemented by oral gavage with P. aeruginosa PA14 WT
3 times a week for 2 weeks (1010 cfu/mouse). The presence of Pseudomonas in
monocolonized or supplemented mice was monitored by plating feces and small
intestine luminal contents on gluten-containing agar media32 and McConkey agar
media incubated for 48 h. For colonization with human microbiota, germ-free mice
received one oral gavage with aspirates from the small intestine of control or
CeD donors at a final concentration of 104 cfu/mouse. A total of 9 aspirates with
bacterial counts of at least 104 cfu/ml from 5 controls and 4 CeD donors were
used for mouse colonization. Bacterial load in the small intestinal aspirates was
estimated by culturing on Brain Hearth Infusion agar media and McConkey agar
media. Each aspirate was sufficient to colonize 2–3 mice.
Gluten treatment. We used a previously validated conventional sensitization
protocol where mice are gavaged with a combination of cholera toxin (CT; 25 µg)
and pepsin/trypsin (PT)-digested gliadin (PT-gliadin; 500 µg) weekly, over a 3-
week period. Following PT-gliadin sensitization, mice were challenged by oral
gavage with 2 mg of sterile gliadin (Sigma-Aldrich) dissolved in acetic acid three
times a week for 2 weeks (gluten treatment). Non-sensitized control mice receiving
CT and saline during the sensitization phase and acetic acid during the challenge
phase were used as sham controls24.
PAR-2 antagonist treatment. To study the role of PAR-2 signaling in vivo, mice
monocolonized with P. aeruginosa PA14 WT were intraperitoneally injected every
3 days with GB83 PAR-2 antagonist (AxonMedChem, The Netherlands) dissolved
in dimethyl sulfoxide (DMSO) at a final concentration 5 mg/kg for 2 weeks.
Control mice received DMSO alone.
Evaluation of enteropathy. At the time of killing, sections of proximal small
intestine were collected in 10% formalin and paraffin embedded. Using rabbit anti-
human primary antibody to CD3 (1:2000; Dako; GA50361–2), CD3+ IELs were
quantified in villus tips of formalin-fixed sections. Slides were examined at ×20
magnification using light microscopy in a blinded fashion. The number of CD3+
IELs per 20 enterocytes was counted from 5 randomly chosen villus tips and
expressed as IELs/100 enterocytes60. Paraffin-embedded sections were stained with
hematoxylin and eosin for histological evaluation of tissue morphology under
light microscopy (Olympus, ON, Canada). Using the Image-Pro 6.3 software
(Mediacybernetics, MD, USA), enteropathy was quantified in a blinded fashion
by measuring 20 villus-to-crypt ratios.
Anti-gliadin antibodies. Antigliadin antibodies in small intestinal washes were
measured by enzyme-linked immunosorbent assay as previously described61, with
some modifications. The 96-well Maxisorp round-bottom polystyrene plates
(Nunc, Roskilde, Denmark) were coated with 50 μl/well of a 0.01 mg/ml solution of
the gliadin extract in 0.1 M carbonate buffer (pH 9.6) or were left uncoated to serve
as control wells. Wells were blocked by incubation with 1% bovine serum albumin.
Serum samples were diluted at 1:100, whereas intestinal wash samples were diluted
at 1:10. The samples were added at 50 μl per well in duplicates and incubated for
1 h. Each plate contained a positive control sample. After washing the wells, they
were incubated with a 1:2000 dilution of either horseradish peroxidase-conjugated
anti-mouse IgG (GE Healthcare, Piscataway, NJ; NA931) or IgA (Abcam, Cam-
bridge, MA; ab97235) secondary antibodies. The antibodies used in this section are
shown in Supplementary Table 4. The plates were washed, and 50 μl of developing
solution was added to each well. Absorbance was measured at 450 nm after 20 min.
Absorbance values were corrected for nonspecific binding by subtraction of the
mean absorbance of the associated bovine serum albumin–coated control wells.
The corrected values were first normalized according to the mean value of the
positive control duplicate on each plate. The mean antibody level for the lasB group
was then set as 1.0 arbitrary units, and other results were normalized accordingly.
Quantification of proteolytic activity. Elastolytic, glutenasic, and mucolytic
activities were measured in small intestinal contents and in bacterial culture
supernatants. Glutenasic activity was also determined in human duodenal biopsies.
Glutenasic and mucolytic activity were measured by bioassay (1.6% agar plates)
using gluten 1% (Sigma-Aldrich) or mucin from porcine stomach type III 0.5%
(Sigma-Aldrich), respectively62. Samples were incubated in the gluten or mucin-
agar plated for 14 h. Amido black was used to stain protein in the mucin bioassay.
Positive proteolytic activity was determined by the presence of a halo surrounding
the inoculation site on substrate-containing media. Elastase activity was analyzed
using Suc-Ala3-pNa (Sigma-Aldrich) or FITC-elastin (AnaSpec) substrates. Briefly,
small intestinal washes or bacterial supernatants were incubated in 50 mM
Tris-HCl buffer pH 8.2 supplemented with 1 mM CaCl2, 50 mM NaCl, and Triton
0.25% at 37 °C with the different substrates. Absorbance and fluorescence were
measured at various time points. Units of enzyme were determined using standard
curves of elastase from porcine pancreas (Sigma-Aldrich). Tryptic activity was
determined using Trypsin Activity Assay Kit from Abcam following the manu-
facturer's recommendations (Abcam, Cambridge, UK).
Bioluminescent imaging. Germ-free and clean SPF mice were gavaged with 1010
cfu P. aeruginosa PA14 expressing a luciferase operon (luxCDABE) under the
control of the lasB promoter. Two weeks after colonization, the gastrointestinal
tract was removed and imaged ex vivo in a Spectrum in vivo Imaging System
(IVIS, Perkin Elmer).
16S-fluorescence in situ hybridization. At the time of killing, sections of prox-
imal small intestine were collected in Carnoy’s fixative and paraffin embedded. The
commercial 16S rRNA gene probe EUB338 (5′-GCTGCCTCCCGTAGGAGT-3′,
Integrated DNA Technologies) was 5′ end-labeled with fluorochrome Cy3 and
then incubated (5 ng/μl) overnight with tissues (Supplementary Table 3). The
hybridization buffer contained 0.9 M NaCl, 20 mM Tris-HCl, pH 7.3, and 0.01%
sodium dodecyl sulfate. Commercial NON338 (IDT) was used as negative control.
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DAPI (4′,6′-diamidino-2-phenylindole) was used to stain DNA in the tissue.
Image-Pro 6.3 software was used to score bacterial encroachment in the epithelium
by counting bacterial signal in contact with 100 enterocytes.
PAR-2 cleavage and expression. Bacterial proteases were incubated with CHO
cells in which NanoLuc luciferase (Nluc) is placed at the PAR-2 N terminus. Then,
1.5 × 104 cells were plated into each well of a 96-well black plate for 24 h. The
cell monolayers were then washed three times with Hank’s balanced salt solution
(HBSS, pH 7.4; Thermofisher), and 100 ml of OptiMeM (Gibco) was added to each
well and cultured for approximately 16 h. Bacteria were incubated for 16 h in
OptiMEM (Gibco) at 37 °C, after which culture medium (20 μl) was added to the
Nluc-expressing cell monolayers (final volume 120 μl) and incubated for 15 min
at 37 °C. Supernatant was collected and centrifuged for 5 min at 12,000 rpm. Then,
80 μl of supernatant was transferred to a 96-multiwell white plate followed by the
addition of 80 μl of 50-fold diluted luciferase assay substrate solution (Promega
Corporation, Madison, WI). Then, the released luciferase activity was measured
using Varioskan (ThermoFisher) in duplicate. Data were normalized for each strain
to the luminescence observed in the WT strains.
PAR-2 expression was quantified in the small intestine of mice using the
rabbit polyclonal antibody raised against amino acids 230–238 of PAR-2 (H-99)
(Santa Cruz Biotechnology, Texas, USA; sc-57797). Sections were incubated with
H-99 antibody diluted 1:500 overnight. A fluorophore-conjugated secondary rabbit
antibody (Alexa Fluor 594 goat anti-rabbit IgG, Life Technologies) was applied
(1:2000) for 1 h (Supplementary Table 4). PAR-2 expression was quantified using
ImageJ and expressed as percent of positive fluorescence/total area on the epithelial
surface of the villi.
Isolation and analysis of IELs. Small intestines were removed from mice and IELs
isolated, as previously described28. Briefly, small intestines from mice were flushed
to remove intestinal contents, Peyer’s patches and mesentery were removed,
intestines opened longitudinally, and cut into 3–5 mm pieces. Intestinal pieces were
incubated in HBSS containing dithiothreitol for 15 min followed by 5–6 incuba-
tions in EDTA/HEPES/HBSS in a 37 °C shaker. After each 15 min of incubation,
intestines were vigorously vortexed and the IELs were collected by passing the
supernatants through a 40 µm cell strainer. IELs were enriched on a Percoll
gradient and resuspended in RNA later for RNA extraction or in fluorescence-
activated cell sorting buffer for cell staining.
Single-cell suspensions of IELs were stained with fluorochrome-labeled cell-
surface antibodies to CD45 (CD45-BV421 (30-F11) BioLegend-103133), CD3
(CD3ε-PE-dazzle 594 (145-2C11) BioLegend-100348), and CD103 (CD103-PE
(3E7) BioLegend-121405) diluted 1:100. The antibodies used in this section are
shown in Supplementary Table 4. Dead cells were excluded using a fixable viability
dye (eBioscience). Total cell counts were determined using CountBright Absolute
Cell Counting Beads (ThermoFisher). Stained cells were acquired using the LSR II
(BD Biosciences) and analyzed with FlowJo software (TreeStar, Ashland, OR).
RNA expression. For RNA extraction from whole tissue, a Tissue-Tearor
Homogenizer (Biospec) was used. RNA was prepared using the RNeasy Mini Kit
(Qiagen). NanoString nCounter gene expression (Mouse Inflammation Panel, 254
genes) was run according to the manufacturer’s instructions (NanoString Tech-
nologies Inc.). The results obtained were analyzed with nSolver 2.5 (NanoString
Technologies). Ratios built from the data were uploaded into IPA software (Qia-
gen) for further analysis. The network score is based on the hypergeometric dis-
tribution and is calculated with the right-tailed Fisher’s exact test.
Microbiota sequencing. Small intestinal contents were collected and flash frozen on
dry ice. DNA was extracted from samples and amplified for the hypervariable 16S
rRNA gene v3 region for sequencing on the Illumina MiSeq platform (Illumina, San
Diego, CA). Briefly, 341F (5′-CCTACGGGAGGCAGCAG-3′) and 518R (5′-
GTATTACCGCGGCTGCTGG-3′) 16S rRNA primers were modified for adaptation
to the Illumina (San Diego, CA) platform and included the addition of 6 bp unique
barcodes to the reverse primer, allowing for multiplex amplification. The amount of
primer used was decreased to 5 pmol each, a Taq polymerase (Life Technologies,
Carlsbad, CA) was used for amplification, and the cycling times were changed to 30 s
for each step. Products were then sequenced using the Illumina MiSeq platform. The
procedure followed main guidelines to facilitate recognition of signals that represent
contamination including the use of proper negative controls63. Processing and ana-
lysis of the data was performed using an in-house pipeline64. Sequences were trimmed
using Cutadapt software (version 1.2.1) and aligned through the PANDAseq software
(version 2.8)65. Operational taxonomic units (OTUs) clustered using Abundan-
tOTU66 were assigned taxonomy according to the Greengenes 2011 reference data-
base67. OTUs observed only once across the data (i.e., singletons) were removed. A
total of 2,633,880 reads were obtained with an average of 75,240.58 per sample and
ranged from 1219 to 155,294 per sample. Alpha-diversity was measured using
Observed species, Chao1, Shannon, and Simpson index. Beta-diversity was calculated
using Bray–Curtis dissimilarity and the distance matrix was used to calculate principal
coordinates and non-metric multidimensional scaling (NMSD). Differences between
whole bacterial communities were tested by permutational multivariate analysis of
variance (PERMANOVA) using Qiime. Differences in taxon composition were
evaluated with Kruskal–Wallis test for multiple samples or Mann–Whitney test for
two independent samples.
Statistical analysis. All the variables were analyzed with SPSS, version 18.0
(SPSS Inc., Chicago, IL). Categorical variables are expressed as numbers and
percentages, and quantitative variables as means ± standard error of the mean (s.e.m.)
or medians with interquartile range for parametric or nonparametric data, respec-
tively. Normal distribution was determined by D’Agustino–Pearson omnibus nor-
mality test, Shapiro–Wilk test and Kolmogorov–Smirnov test with Dallal-Wilkinson-
Lillie correction. Data are depicted as dot plots, with each dot representing an indi-
vidual human or mouse, or biological replicate. The one-way analysis of variance
(ANOVA) test was used to evaluate differences between more than two groups with a
parametric distribution and Tukey's correction was applied. Student’s t-test (two-
tailed) was performed to evaluate the differences between two independent groups or
paired samples as appropriate. Data with nonparametric distribution were evaluated
with Kruskal–Wallis test for more than two groups, and Mann–Whitney test for two
independent groups. Student’s t-test and multiple t-tests were used by nSolver 2.5 for
statistical analysis of gene expression. Spearman's rank correlation coefficient was
used to measure nonparametric rank correlation. A P value < 0.05 was selected to
reject the null hypothesis by two-tailed tests. Information regarding specific P values,
value of n, and how data are presented can be found in figure legends.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data presented in the manuscript are found in the NCBI database, under the
Umbrella BioProject: PRJNA51889. This project contains the Nanostring Raw data
deposited in Gene Expression Omnibus database GSE125983 and the sequencing data
deposited in Sequence Read Archive (SRA, SRP136344).
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